CVS Health Corporation (CVS) Bundle
A Brief History of CVS Health
CVS Health Corporation has undergone significant transformations and growth leading into 2024. As of September 30, 2024, the company's financial performance highlights its ongoing strategic initiatives and challenges.
Financial Performance (2024)
For the three months ended September 30, 2024, CVS Health reported total revenues of $95.428 billion, an increase from $89.764 billion in the same period in 2023, marking a growth of 6.3%.
| Metric | Q3 2024 | Q3 2023 | Change ($) | Change (%) |
|---|---|---|---|---|
| Total Revenues | $95.428 billion | $89.764 billion | $5.664 billion | 6.3% |
| Net Income | $87 million | $2.261 billion | ($2.174 billion) | (96.2%) |
| Operating Income | $832 million | $3.690 billion | ($2.858 billion) | (77.5%) |
Segments of Revenue
The revenue growth was primarily driven by the Health Care Benefits and Pharmacy & Consumer Wellness segments, although there was a decline in the Health Services segment.
| Segment | Q3 2024 Revenue | Q3 2023 Revenue |
|---|---|---|
| Health Care Benefits | $32.996 billion | $26.296 billion |
| Health Services | $44.129 billion | $46.891 billion |
| Pharmacy & Consumer Wellness | $32.423 billion | $28.872 billion |
Operating Expenses and Losses
Operating expenses rose significantly, totaling $94.596 billion in Q3 2024, compared to $86.074 billion in Q3 2023, resulting in an increase of 9.9%.
Restructuring charges also saw a significant increase, totaling $1.169 billion in Q3 2024, compared to $11 million in Q3 2023, reflecting the company's strategic realignment efforts.
Healthcare Costs
Health care costs increased to $29.922 billion in Q3 2024 from $21.499 billion in Q3 2023, indicating a rise of 39.4%.
Investment Income
Net investment income for Q3 2024 increased to $550 million, up from $277 million in Q3 2023, driven by improved market conditions.
Cash Flow and Liquidity
CVS Health reported net cash provided by operating activities of $7.247 billion for the nine months ended September 30, 2024, down from $16.062 billion in the prior year, a decrease of 54.9%.
| Cash Flow Metrics | 2024 | 2023 | Change ($) | Change (%) |
|---|---|---|---|---|
| Net Cash Provided by Operating Activities | $7.247 billion | $16.062 billion | ($8.815 billion) | (54.9%) |
| Net Cash Used in Investing Activities | ($7.066 billion) | ($19.647 billion) | $12.581 billion | 64.0% |
| Net Cash Provided by (Used in) Financing Activities | ($1.566 billion) | $3.655 billion | ($5.221 billion) | (142.8%) |
Debt and Capital Structure
As of September 30, 2024, CVS Health had $800 million of commercial paper outstanding at a weighted average interest rate of 5.00%, and entered into a $3.0 billion term loan credit agreement in March 2024.
Additionally, long-term borrowings included the issuance of $5.0 billion in senior notes in May 2024.
The company's total debt stood at approximately $40 billion as of September 30, 2024, reflecting its strategic acquisitions and ongoing operational investments.
Shareholder Equity
As of September 30, 2024, CVS Health's total shareholders' equity was approximately $75.106 billion compared to $76.636 billion at the end of 2023.
The company has continued to implement share repurchase programs, with approximately $3.0 billion spent on repurchasing shares in the first nine months of 2024.
CVS Health's robust financial metrics, along with its strategic adjustments and focus on growth areas, position it as a significant player in the healthcare sector as it heads into 2024.
A Who Owns CVS Health Corporation (CVS)
Ownership Structure
The ownership of CVS Health Corporation (CVS) is distributed among various institutional and individual shareholders. As of 2024, the total number of shares outstanding is approximately 1.777 billion shares. The company has a treasury stock of 519 million shares, resulting in a net share count of around 1.258 billion shares held by the public.
Major Shareholders
The following table outlines the major shareholders of CVS Health Corporation as of 2024:
| Shareholder | Ownership Percentage | Type of Holder |
|---|---|---|
| Vanguard Group, Inc. | 8.5% | Institutional Investor |
| BlackRock, Inc. | 7.9% | Institutional Investor |
| State Street Corporation | 4.4% | Institutional Investor |
| Wellington Management Company, LLP | 4.1% | Institutional Investor |
| FMR LLC (Fidelity) | 3.5% | Institutional Investor |
| Mutual of America Capital Management LLC | 2.2% | Institutional Investor |
| Other Individual and Institutional Investors | 65.4% | Various |
Insider Ownership
Insider ownership, including executives and board members, accounts for approximately 0.5% of the total shares outstanding. This includes options and restricted stock units. Key executives such as the CEO and CFO hold significant portions of their compensation in stock options, aligning their interests with shareholders.
Market Performance Indicators
As of September 30, 2024, CVS Health Corporation reported a market capitalization of approximately $67.5 billion. The stock price has fluctuated between $50 and $75 over the past year, reflecting broader market trends and company performance.
Shareholder Equity
The following table provides an overview of CVS Health's shareholder equity as of September 30, 2024:
| Equity Component | Value (in millions) |
|---|---|
| Common Stock | $49,510 |
| Treasury Stock | $(36,813) |
| Retained Earnings | $62,038 |
| Accumulated Other Comprehensive Income | $209 |
| Total Shareholders' Equity | $75,106 |
Dividend Policy
CVS Health Corporation has consistently paid dividends, with a declared dividend of $0.665 per share for the third quarter of 2024. Year-to-date, the total dividends declared amount to $1.995 per share.
Share Repurchase Programs
The company has authorized share repurchase programs totaling $10 billion, with $1.5 billion remaining as of September 30, 2024. In the first nine months of 2024, CVS repurchased approximately 39.7 million shares at a cost of around $3.0 billion.
CVS Health Corporation (CVS) Mission Statement
Overview of CVS Health's Mission Statement
CVS Health Corporation's mission statement emphasizes its commitment to providing accessible and affordable health care services. The company aims to improve the health of its customers and communities through innovative services and products.
Financial Performance and Relevant Statistics
As of September 30, 2024, CVS Health reported total revenues of $95.4 billion for the quarter, reflecting an increase of 6.3% compared to the previous year. The breakdown of revenues is as follows:
| Revenue Type | Q3 2024 (in millions) | Q3 2023 (in millions) | Change (%) |
|---|---|---|---|
| Products | 59,674 | 61,298 | -2.7% |
| Premiums | 30,925 | 24,657 | 25.4% |
| Services | 4,279 | 3,532 | 21.1% |
| Net Investment Income | 550 | 277 | 98.7% |
| Total Revenues | 95,428 | 89,764 | 6.3% |
Net Income and Earnings Per Share
For the third quarter of 2024, CVS Health reported a net income of $71 million, a significant decrease from $2.3 billion in the same quarter of 2023. Earnings per share (EPS) for the quarter were as follows:
| Type | Q3 2024 | Q3 2023 |
|---|---|---|
| Basic EPS | $0.07 | $1.76 |
| Diluted EPS | $0.07 | $1.75 |
Operating Costs and Income
CVS Health's operating costs for the third quarter of 2024 reached $94.6 billion, compared to $86.1 billion in the previous year. The operating income for the same period was reported at $832 million, down from $3.7 billion in Q3 2023.
| Cost Type | Q3 2024 (in millions) | Q3 2023 (in millions) | Change (%) |
|---|---|---|---|
| Cost of Products Sold | 52,948 | 54,688 | -3.2% |
| Health Care Costs | 29,922 | 21,499 | 39.3% |
| Operating Expenses | 10,557 | 9,876 | 6.9% |
| Restructuring Charges | 1,169 | 11 | 10,527.3% |
| Total Operating Costs | 94,596 | 86,074 | 9.9% |
Market Performance and Shareholder Returns
CVS Health's dividend declared per share as of September 30, 2024, was $0.665, an increase from $0.605 in the previous year. The company's share repurchase program has also been active, with approximately 39.7 million shares repurchased for about $3.0 billion in the nine months ending September 30, 2024.
| Share Repurchase Program | Authorization Date | Authorized Amount (in billions) | Remaining (in billions) as of September 30, 2024 |
|---|---|---|---|
| 2022 Repurchase Program | November 17, 2022 | $10.0 | $10.0 |
| 2021 Repurchase Program | December 9, 2021 | $10.0 | $1.5 |
Conclusion
CVS Health Corporation continues to focus on its mission of improving health outcomes while navigating challenges in the healthcare sector. The company remains committed to delivering value to its shareholders through strategic initiatives and operational efficiencies.
How CVS Health Corporation (CVS) Works
Overview of CVS Health Corporation
CVS Health Corporation operates as an integrated healthcare company, focusing on health services, pharmacy, and retail. As of 2024, CVS continues to expand its reach through various segments, including Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness.
Financial Performance
For the nine months ending September 30, 2024, CVS Health reported total revenues of $275.1 billion, marking an increase of 4.2% compared to the same period in 2023. The breakdown of revenues is as follows:
| Segment | 2024 Revenue (in millions) | 2023 Revenue (in millions) | Change ($) | Change (%) |
|---|---|---|---|---|
| Health Care Benefits | $97,707 | $74,079 | $23,628 | 31.9% |
| Health Services | $126,585 | $133,428 | ($6,843) | (5.1%) |
| Pharmacy & Consumer Wellness | $90,986 | $67,371 | $23,615 | 35.0% |
| Corporate/Other | $368 | $38 | $330 | 868.4% |
| Total | $275,099 | $263,963 | $11,136 | 4.2% |
Operating Costs and Income
CVS Health's operating costs for the nine months ended September 30, 2024, totaled $268.9 billion, resulting in an operating income of $6.1 billion. Key operating costs are detailed below:
| Cost Type | 2024 Amount (in millions) | 2023 Amount (in millions) |
|---|---|---|
| Cost of Products Sold | $151,019 | $159,679 |
| Health Care Costs | $85,578 | $63,729 |
| Operating Expenses | $31,185 | $29,329 |
| Restructuring Charges | $1,169 | $507 |
| Total Operating Costs | $268,951 | $253,593 |
Segment Analysis
The performance of CVS Health's segments varies significantly, reflecting different market conditions and operational challenges:
- Health Care Benefits: Increased revenues driven by higher enrollment in Medicare and Medicaid programs.
- Health Services: Decline in revenues primarily due to the loss of a major client and reimbursement pressures.
- Pharmacy & Consumer Wellness: Growth attributed to increased prescription volume and contributions from vaccination services.
Net Income and Earnings Per Share
For the nine months ended September 30, 2024, CVS Health reported a net income of $2.963 billion, with earnings per share (EPS) as follows:
| Measure | 2024 | 2023 |
|---|---|---|
| Basic EPS | $2.36 | $4.90 |
| Diluted EPS | $2.35 | $4.88 |
Cash Flow Analysis
The cash flow statement for the nine months ended September 30, 2024, indicates a net cash provided by operating activities of $7.247 billion, compared to $16.062 billion in 2023. Key figures include:
| Cash Flow Type | 2024 (in millions) | 2023 (in millions) |
|---|---|---|
| Net Cash Provided by Operating Activities | $7,247 | $16,062 |
| Net Cash Used in Investing Activities | ($7,066) | ($19,647) |
| Net Cash Provided by Financing Activities | ($1,566) | $3,655 |
Debt Management
As of September 30, 2024, CVS Health had total debt obligations that included:
- Long-term Debt: Approximately $30 billion
- Short-term Borrowings: $800 million outstanding at a weighted average interest rate of 5.00%
Market Position and Strategy
CVS Health focuses on integrating healthcare services to enhance patient outcomes while managing costs. Its strategy includes:
- Expansion of Health Services: Through acquisitions like Oak Street Health and Signify Health.
- Enhancing Pharmacy Services: Increasing the volume of prescriptions filled and promoting generic drug use.
- Digital Transformation: Investing in technology to streamline operations and improve customer engagement.
How CVS Health Corporation (CVS) Makes Money
Revenue Streams
CVS Health Corporation generates revenue through several key segments, primarily including Products, Premiums, and Services.
| Revenue Type | Q3 2024 (in millions) | Q3 2023 (in millions) | 9M 2024 (in millions) | 9M 2023 (in millions) |
|---|---|---|---|---|
| Products | $59,674 | $61,298 | $169,610 | $179,984 |
| Premiums | $30,925 | $24,657 | $91,983 | $74,117 |
| Services | $4,279 | $3,532 | $12,108 | $8,977 |
| Net Investment Income | $550 | $277 | $1,398 | $885 |
| Total Revenues | $95,428 | $89,764 | $275,099 | $263,963 |
Operating Costs
Operating costs for CVS include the cost of products sold, health care costs, operating expenses, and restructuring charges.
| Cost Type | Q3 2024 (in millions) | Q3 2023 (in millions) | 9M 2024 (in millions) | 9M 2023 (in millions) |
|---|---|---|---|---|
| Cost of Products Sold | $52,948 | $54,688 | $151,019 | $159,679 |
| Health Care Costs | $29,922 | $21,499 | $85,578 | $63,729 |
| Operating Expenses | $10,557 | $9,876 | $31,185 | $29,329 |
| Restructuring Charges | $1,169 | $11 | $1,169 | $507 |
| Total Operating Costs | $94,596 | $86,074 | $268,951 | $253,593 |
Profitability Metrics
CVS's profitability has been impacted by various factors, including operating income, interest expense, and net income.
| Metric | Q3 2024 (in millions) | Q3 2023 (in millions) | 9M 2024 (in millions) | 9M 2023 (in millions) |
|---|---|---|---|---|
| Operating Income | $832 | $3,690 | $6,148 | $10,370 |
| Interest Expense | $752 | $693 | $2,200 | $1,968 |
| Net Income | $71 | $2,265 | $2,963 | $6,321 |
| Net Income Attributable to CVS Health | $87 | $2,261 | $2,970 | $6,298 |
Segment Performance
CVS operates across several segments, each contributing to the overall revenue and profitability.
| Segment | Q3 2024 Revenue (in millions) | Q3 2023 Revenue (in millions) |
|---|---|---|
| Health Care Benefits | $32,996 | $44,129 |
| Health Services | $44,129 | $46,891 |
| Pharmacy & Consumer Wellness | $32,423 | $28,872 |
Market Trends and Influences
CVS's performance is influenced by market dynamics, including prescription volume, generic dispensing rates, and changes in consumer demand.
- Pharmacy same store sales increased by 12.1% in the nine months ended September 30, 2024.
- Generic dispensing rate was 89.5% for the nine months ended September 30, 2024.
- Prescriptions filled increased by 6.0% on a 30-day equivalent basis in Q3 2024 compared to the prior year.
Investment and Capital Management
CVS continues to manage its capital effectively, focusing on growth and shareholder returns.
| Capital Management Metric | Q3 2024 (in millions) | Q3 2023 (in millions) |
|---|---|---|
| Dividends Declared per Share | $0.665 | $0.605 |
| Weighted Average Shares Outstanding (Basic) | 1,259 | 1,287 |
| Net Cash Provided by Operating Activities | $7,247 | $16,062 |
CVS Health Corporation (CVS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- CVS Health Corporation (CVS) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of CVS Health Corporation (CVS)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View CVS Health Corporation (CVS)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.